Sitilop Master Meeting

Prof Marios Politis of the Sitilop team hosted the 1st annual Master Meeting with the help of Heather Wilson, Dr Edoardo de Natale and Dr Chloe Farrell. The team had the chance to listen to presentations detailing motivational and intriguing plans for the year to come. Inspiring new ideas were exchanged between its members.

Sitilop was present at the International Congress of Parkinson’s Disease and Movement Disorders

13 members of Sitilop team attended the International Congress of Parkinson’s Disease and Movement Disorders in Nice, France. It was a great opportunity to interact with fellow researchers and collaborators; ideas were exchanged and opinions were expressed between great minds of the field. This environment evolves our understanding on how we can work together with…

Details

Sitilop is collaborating with Life Molecular Imaging and Invicro on a new way of evaluating Tau depositions in Progressive Supranuclear Palsy

Progressive Supranuclear Palsy is a rare neurodegenerative disorder characterised by the presence of 4-repeat tau pathology. Progressive Supranuclear Palsy is regarded as a spectrum of different phenotypes characterised by predominant motor, cognitive, speech, or behavioural impairment. No therapy is available for this disease and symptomatic treatment offers only limited benefit. Sitilop is collaborating with Life…

Details

Sitilop is collaborating with Life Molecular Imaging on a new way of evaluating Tau depositions in Alzheimer’s disease

Alzheimer’s disease is the most common cause of dementia worldwide. It is a progressive neurodegenerative disorder for which we currently have no cure or disease modifying therapies to slow disease progression. Alzheimer’s disease is often preceded by a prodromal phase called mild cognitive impairment which is characterised by decline in cognitive performance. Neuropathological hallmarks of…

Details

Sitilop is collaborating with United Neuroscience on a new observational trial in Parkinson’s disease

Parkinson’s disease is the second most common neurodegenerative disorder characterised by the cardinal motor symptoms of bradykinesia, rigidity and tremor; as well as a variety of non-motor symptoms such as sleep problems, cognitive decline and autonomic dysfunction. The neuropathological hallmark of Parkinson’s disease is the presence of α-synuclein (SNCA) aggregates, which form the main components…

Details